| Related Articles |
The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis.
Expert Rev Anticancer Ther. 2019 May 19;:
Authors: Qin Q, Peng B, Li B
Abstract
OBJECTIVES: To investigate the impact of EGFR mutations on the efficacy of definitive chemoradiotherapy (CRT) in patients with locally advanced unresectable stage III NSCLC.
METHODS: PubMed and EMBASE were searched for eligible studies which compared clinical outcomes according to EGFR status among patients with locally advanced unresectable NSCLC treated with definitive CRT. Efficacy outcomes included objective response rate (ORR), overall disease progression, local regional recurrence (LRR), distant progression (DP), brain metastasis, progression-free survival (PFS) and overall survival (OS). Meta-analysis was performed when relevant data were available.
RESULTS: The authors identified seven eligible studies including 695 patients. No significant difference was detected in ORR (Risk Ratio [RR] 1.13, 95% confidence interval [CI] 0.91-1.39, P=0.28) and overall disease progression (RR 1.06, 95% CI 0.95-1.19, P=0.29) between EGFR-mutant and EGFR-wild type groups. EGFR-mutant group had significantly lower LRR (RR 0.49, 95% CI 0.33-0.72, P<0.01), higher DP (RR 1.36, 95% CI 1.18-1.55, P<0.01) and higher brain metastasis (RR 2.48, 95%CI 1.46-4.20, P<0.01) than the EGFR-wild type group. No sufficient data were available to perform pooled analysis regarding PFS and OS.
CONCLUSION: For patients with locally advanced unresectable stage III NSCLC treated with definitive CRT, the presence of EGFR mutations may be indicative of lower locoregional recurrence and higher distant progression, especially brain metastasis.
OBJECTIVES: To investigate the impact of EGFR mutations on the efficacy of definitive chemoradiotherapy (CRT) in patients with locally advanced unresectable stage III NSCLC.
METHODS: PubMed and EMBASE were searched for eligible studies which compared clinical outcomes according to EGFR status among patients with locally advanced unresectable NSCLC treated with definitive CRT. Efficacy outcomes included objective response rate (ORR), overall disease progression, local regional recurrence (LRR), distant progression (DP), brain metastasis, progression-free survival (PFS) and overall survival (OS). Meta-analysis was performed when relevant data were available.
RESULTS: The authors identified seven eligible studies including 695 patients. No significant difference was detected in ORR (Risk Ratio [RR] 1.13, 95% confidence interval [CI] 0.91-1.39, P=0.28) and overall disease progression (RR 1.06, 95% CI 0.95-1.19, P=0.29) between EGFR-mutant and EGFR-wild type groups. EGFR-mutant group had significantly lower LRR (RR 0.49, 95% CI 0.33-0.72, P<0.01), higher DP (RR 1.36, 95% CI 1.18-1.55, P<0.01) and higher brain metastasis (RR 2.48, 95%CI 1.46-4.20, P<0.01) than the EGFR-wild type group. No sufficient data were available to perform pooled analysis regarding PFS and OS.
CONCLUSION: For patients with locally advanced unresectable stage III NSCLC treated with definitive CRT, the presence of EGFR mutations may be indicative of lower locoregional recurrence and higher distant progression, especially brain metastasis.
PMID: 31104529 [PubMed - as supplied by publisher]
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου